Samsung Medical Center
π°π·South Korea
- Country
- π°π·South Korea
- Ownership
- Subsidiary
- Established
- 1994-01-01
- Employees
- 501
- Market Cap
- -
Prognostic Relevance of Biological Subtype in Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2017-05-01
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 202
- Registration Number
- NCT02063906
- Locations
- π°π·
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of
Xeloda Maintenance Versus BSC in Metastatic Colorectal Cancer
- First Posted Date
- 2014-02-12
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT02060669
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma
Completed
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Other: EBER
- First Posted Date
- 2014-02-12
- Last Posted Date
- 2014-02-12
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 571
- Registration Number
- NCT02060435
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Prognostic Molecular Markers in Patients With Myelodysplastic Syndrome
Completed
- Conditions
- Myelodysplastic Syndrome
- Interventions
- Genetic: spliceosome
- First Posted Date
- 2014-02-12
- Last Posted Date
- 2014-02-12
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 58
- Registration Number
- NCT02060409
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Platelet Response During the Second Cycle of Decitabine Can Predict Response and Survival for Myelodysplastic Syndrome
- Conditions
- Myelodysplastic Syndrome
- First Posted Date
- 2014-01-27
- Last Posted Date
- 2014-01-27
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT02045654
- Locations
- π°π·
Division of Hematology Oncology, Samsung Medical Center, Seoul, Korea, Republic of
Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia
Phase 4
Completed
- Conditions
- Neurogenic Lower Urinary Tract Dysfunction
- Interventions
- Drug: Naftofidil
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2019-12-02
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 194
- Registration Number
- NCT02034604
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Comparison Between Invasive Pressure Flow Study and Non-invasive Penile Cuff Test
Completed
- Conditions
- Bladder Outlet ObstructionPressure Flow Study
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2019-12-02
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 335
- Registration Number
- NCT02031653
- Locations
- π°π·
Samsung Medical Center, Seoul,, Korea, Republic of
Biomarker Analysis in Metastatic Colorectal Cancer Treated With Cetuximab
Completed
- Conditions
- Colorectal Cancer
- First Posted Date
- 2014-01-07
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT02029326
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer Patients
- First Posted Date
- 2014-01-03
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 43
- Registration Number
- NCT02026583
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis
Phase 2
Completed
- Conditions
- HER2-positive Gastric Cancer Patients With Liver Metastasis
- Interventions
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 32
- Registration Number
- NCT02015169
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Korea, Republic of